IP Library › Granted Patent US 12,630,644
Granted Patent B2
US 12,630,644 · App. 19/017,195 · Granted May 19, 2026

Anti-CD40 single-domain antibody, and preparation method therefor and use thereof

Inventors: Jiwen Du (Shanghai, CN); Jing Xue (Shanghai, CN); Yan Yang (Shanghai, CN); Yafeng Yuan (Shanghai, CN); Yinhui Xu (Shanghai, CN); Hui Ding (Shanghai, CN); Yufang Wang (Shanghai, CN); Changchun Zha (Shanghai, CN)
Assignee: BIOINTRON BIOLOGICAL INC.
C07K16/2878G01N33/53C07K2317/565C07K2317/569G01N2333/70578
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,630,644
App. No.
19/017,195
Granted
May 19, 2026
Kind
B2
Abstract

The present invention relates to the technical field of molecular biology, and in particular, to an anti-CD40 nanobody, and a preparation method therefor and use thereof. The anti-CD40 nanobody provided by the present invention has three unique complementarity determining regions, namely CDR1, CDR2, and CDR3. The present invention further provides a sequence encoding the nanobody or its VHH chain, a corresponding expression vector, and a host cell capable of expressing the nanobody. The present invention includes immunizing an alpaca by constructing a CD40 antigen to obtain a PBMC of the alpaca and constructing a vector; screening an anti-CD40 antibody through phage display; and finally obtaining a highly sensitive and specifically binding antibody through functional assays and sequencing result analysis. The nanobody provided by the present invention can specifically recognize and bind to CD40.

Claims (4)

1 . An anti-CD40 single-domain antibody, comprising framework regions and complementarity determining regions (CDRs), wherein the CDRs comprise CDR1, CDR2, and CDR3, respectively corresponding to SEQ ID NO. 42, SEQ ID NO. 20, and SEQ ID NO. 21 in sequence.

2 . The anti-CD40 single-domain antibody of claim 1 , wherein an amino acid sequence of the anti-CD40 single-domain antibody is SEQ ID NO. 29.

3 . The anti-CD40 single-domain antibody of claim 1 , wherein a nucleotide sequence encoding the amino acid sequence of the anti-CD40 single-domain antibody is SEQ ID NO. 37.

4 . A type I transmembrane protein assay kit, comprising the anti-CD40 single-domain antibody according to claim 1 and known concentration of CD40 protein.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 10, 2025
From: DU, JIWEN; XUE, JING; YANG, YAN; YUAN, YAFENG; XU, YINHUI; DING, HUI; WANG, YUFANG; ZHA, CHANGCHUN
To: BIOINTRON BIOLOGICAL INC.
Reel/Frame 069824/0845 →
Priority Claims (1)
CN 202211078773.2 · Sep 5, 2022 · national
Continuity (2)
Continuation PCTCN2023077183 · Feb 20, 2023
Related Publication 20250188180A1 · Jun 12, 2025
References Cited (5)
US 9475879B2 · Suri · 2016 [cited by examiner]
US 11220550B2 · Yamniuk · 2022 [cited by examiner]
US 20160311916A1 · Ellmark · 2016 [cited by applicant]
US 20210155705A1 · Yang et al. · 2021 [cited by applicant]
US 20220135694A1 · Van Der Vliet et al. · 2022 [cited by applicant]